Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura

Thrombotic thrombocytopenic purpura (TTP) is a serious and rare disease diagnosed by < 10% activity of disintegrin and metalloprotease with thrombospondin type-I repeats-13 (ADAMTS13). About 75% of cases are of immune-mediated origin (iTTP), with detectable anti-ADAMTS13 blocking autoantibodies. 1,2 Onset is usually sudden, with profound thrombocytopenia, microangiopathic hemolytic anemia